Effects of Crit-Line® Monitor Use on Patient Outcomes and Epoetin Alfa Dosing following Onset of Hemodialysis: A Propensity Score-Matched Study
Autor: | Jose A. Diaz-Buxo, Mayuri Thakuria, Linda H. Ficociello, Thomas J. Alfieri, Scott P. Sibbel, Michael Black, Claudy Mullon |
---|---|
Rok vydání: | 2014 |
Předmět: |
Male
medicine.medical_specialty Anemia Iron medicine.medical_treatment Blood volume Hematocrit Iron sucrose End stage renal disease Renal Dialysis Internal medicine Humans Medicine Propensity Score Erythropoietin Dialysis Aged Monitoring Physiologic Retrospective Studies medicine.diagnostic_test business.industry Transferrin Epoetin alfa Hematology General Medicine Middle Aged medicine.disease Recombinant Proteins Surgery Epoetin Alfa Oxygen Nephrology Hematinics Female Hemodialysis business Blood Chemical Analysis medicine.drug |
Zdroj: | Blood Purification. 37:249-257 |
ISSN: | 1421-9735 0253-5068 |
DOI: | 10.1159/000362107 |
Popis: | Background: The Crit-Line® monitor (CLM) is a device for monitoring hematocrit, oxygen saturation and change in intravascular blood volume during hemodialysis. Prior studies have evaluated CLM use in dialysis patients, but not specifically in those new to dialysis. Methods: In this retrospective analysis, 199 patients initiating dialysis at 8 facilities routinely using CLM were compared with 796 propensity score-matched non-CLM patients initiating dialysis at facilities not using CLM. Outcomes were considered over the first 180 days on dialysis. Results: Overall, the CLM group had higher StdKt/V (p = 0.06) and received lower doses of intravenous iron than the non-CLM group (p < 0.001). Erythropoiesis-stimulating agent doses were lower in the CLM group in months 1-5. Serum iron and transferrin saturation levels were higher overall for the CLM group than the non-CLM group (p = 0.004 and 0.01, respectively). Hemoglobin levels and time to first hospitalization were similar for both groups. Conclusion: Use of CLM is associated with lower erythropoiesis-stimulating agent and iron use in incident hemodialysis patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |